TCM Biotech International Return on Equity

TCM Biotech International's return on equity stands at 3.81%. That is above the Healthcare sector average of -75.84%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

TCM Biotech International sits higher the Healthcare benchmark (-75.84%) with a ROE of 3.81%. That is roughly 105.0% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of 3.81% for TCM Biotech International means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how TCM Biotech International's ROE evolved across reporting periods, while the comparison chart places 4169.TW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. TCM Biotech International's reading of 3.81% (sector avg -75.84%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.